REPL - Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? | Benzinga
Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
Bristol-Myers Squibb Co’s (NYSE:BMY) Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat several types of cancer.
The results show that one-third of patients receiving RP1 plus nivolumab responded to treatment, improving upon the investigator-assessed data presented at ASCO 2024. All responses lasted longer than 6 months from baseline.
“The overall strength ...